10-Q: BioAdaptives Faces Going Concern Amidst Revenue Drop

BioAdaptives Inc. reported a significant decline in revenue and increased operating expenses, raising substantial doubt about its ability to continue as a going concern.

Summary

• BioAdaptives Inc. reported a net loss of $355,050 for the six months ended June 30, 2025, an improvement from a $489,724 net loss in the prior year, primarily due to a $192,613 gain from changes in derivative liabilities.
• Revenue for the six months ended June 30, 2025, significantly decreased to $3,219 from $12,669 in the same period last year.
• Gross profit fell to $1,063 for the six months ended June 30, 2025, compared to $4,030 in the prior year.
• Operating expenses surged to $529,430 for the six months ended June 30, 2025, up from $146,840 in the previous year, driven by increases in general and administrative fees ($341,275 vs. $36,289) and professional fees ($187,155 vs. $69,260).
• The company incurred a loss from operations of $528,367 for the six months ended June 30, 2025, a substantial increase from $142,810 in the prior year.
• Cash on hand as of June 30, 2025, was $210,582, up from $137,470 at December 31, 2024.
• Total current liabilities decreased to $1,407,813 as of June 30, 2025, from $1,725,803 at December 31, 2024.
• The accumulated deficit reached $9,518,356 as of June 30, 2025.
• The company is in default on convertible debentures originated in 2018, which were due in 2020, and is working on an alternative resolution.
• New products like MyndMed (cognitive enhancement), Xcellara (stem cell activator), Zeranovia (weight loss), and PawPa Regen (dog treats) are being launched or are in development/market testing.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, including a going concern warning, significant revenue decline, and increased operating losses. While new products are being launched and some capital was raised, the overall financial health is very weak, and the company is in default on existing debt. The internal control weaknesses further compound the negative outlook.

Positives

• Net loss decreased to $355,050 for the six months ended June 30, 2025, from $489,724 in the prior year, primarily due to a $192,613 gain on the change in fair value of derivative liabilities.
• Cash balance increased to $210,582 as of June 30, 2025, from $137,470 at December 31, 2024.
• Working capital deficiency improved to $(1,152,298) as of June 30, 2025, from $(1,921,712) as of June 30, 2024.
• The company is actively launching new products, including MyndMed, Xcellara, Zeranovia, and PawPa Regen dog treats, with PawPa Regen accepted by Amazon for Q3 sale.
• Zeranovia, a weight loss supplement, is finishing its clinical trial for a Q4 launch, with encouraging market testing results of 5 to 11 pounds loss in 7 to 10 days.

Negatives

• Revenue for the six months ended June 30, 2025, significantly declined to $3,219 from $12,669 in the comparable prior year period.
• Gross profit decreased substantially to $1,063 for the six months ended June 30, 2025, from $4,030 in the prior year.
• Operating expenses increased significantly to $529,430 for the six months ended June 30, 2025, from $146,840 in the prior year, leading to a larger operating loss.
• Cash used in operating activities increased to $208,888 for the six months ended June 30, 2025, compared to $92,637 in the prior year.
• The company has an accumulated deficit of $9,518,356 as of June 30, 2025.
• The company is currently in default on convertible debentures originated in 2018.
• Management concluded that internal control over financial reporting was not effective as of June 30, 2025, due to material weaknesses including inadequate segregation of duties and insufficient written policies.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to accumulated losses and insufficient cash to operate for the next twelve months.
• The company's ability to raise additional capital through future issuances of common stock is uncertain, and obtaining additional financing is necessary for continued operations.
• Remediation efforts for identified material weaknesses in internal control over financial reporting (inadequate segregation of duties, ineffective risk assessment, insufficient written policies) are dependent on securing additional financing.
• The company is currently in default on certain convertible debentures, which could lead to further financial or legal complications.
• Anticipates incurring further losses in the near future until all new products are launched and sales are maximized.

Future Outlook

The company anticipates incurring losses in the near future until all new products are launched and sales are maximized. Management plans to raise capital through equity markets to fund future operations, seek additional acquisitions, and generate revenue through its business. The success of the business plan beyond the next 12 months is contingent upon obtaining additional financing.

Management Comments

• "We anticipate to be incurring some losses in the near future, until all the products are launch and have maximized their sales."
• "Our ability to continue as a going concern is dependent upon our ability to successfully compete, operate profitably and/or raise additional capital through other means."
• "We believe that increasing our marketing expenses will be critical to establishing sales sufficient to cover our expenses and, if possible, generate a profit."
• "Managements plans include the raising of capital through the equity markets to fund future operations, seeking additional acquisitions, and generating revenue through our business."

Industry Context

BioAdaptives operates in the health and wellness industry, focusing on natural plant, fungi, and algal-based products, as well as medical devices. The company is expanding its product lines into areas like cognitive health (nootropics), regenerative medicine (stem cell activation), and weight management, aligning with growing consumer interest in natural health solutions and personalized wellness. Its direct-to-consumer digital marketing and telehealth partnerships reflect a broader industry trend towards accessible, technology-driven health solutions. The entry into the pet wellness market with PawPa Regen also taps into the expanding pet care industry.

Comparison to Industry Standards

• The company's significant accumulated deficit of over $9.5 million and ongoing operating losses are well below industry standards for sustainable growth, indicating severe financial distress.
• The substantial doubt about the company's ability to continue as a going concern is a critical red flag, contrasting sharply with financially stable companies in the nutraceutical and medical device sectors.
• The reported revenue of $3,219 for six months is extremely low for a publicly traded company, especially when compared to established players in the dietary supplement market like Herbalife Nutrition (HLF) or Nature's Bounty, which generate hundreds of millions or billions in revenue.
• The high increase in general and administrative and professional fees relative to minimal revenue suggests inefficient cost management compared to industry peers who typically scale expenses with revenue growth.
• The default on convertible debentures indicates a failure to meet financial obligations, a stark contrast to companies with strong balance sheets and access to capital markets.

Management Changes

Corporate Governance

Related Party Transactions

• Employment agreement with the Chief Executive Officer (James E. Keener) for a salary of $300,000 per annum, with $150,000 payroll expense recorded for the six months ended June 30, 2025, and 18,955 shares of Series D Preferred Stock issued for payroll.
• Employment agreement with a director for a salary of $5,000 per month, with $30,000 payroll expense recorded for the six months ended June 30, 2025, and 3,791 shares of Series D Preferred Stock issued for payroll.
• Employment agreement with another director for a salary of $5,000 per month, with $25,000 payroll expense recorded for the six months ended June 30, 2025, and 2,842 shares of Series D Preferred Stock issued for payroll.
• Granted stock option of 500,000 shares of common stock to a director for compensation, valued at $28,670, fully vested on grant date of April 16, 2025.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future equity raises and conversions of preferred stock/convertible notes. The going concern warning indicates a high risk of capital loss. Current operational performance is poor, impacting shareholder value.
• **Employees:** The company has one full-time executive and relies on hourly labor and consultants, suggesting limited job security and growth opportunities within the company.
• **Creditors:** The company is in default on convertible debentures, indicating a risk of non-payment or delayed payment, which could lead to legal action or further financial restructuring.
• **Customers:** New product launches (PawPa Regen, MyndMed, Xcellara, Zeranovia) could offer new health and wellness solutions, but the company's financial instability might raise concerns about long-term product support or availability.
• **Suppliers:** The company's financial instability and reliance on future financing could pose payment risks for suppliers.

Next Steps

• Launch of PawPaRegen dog treats on Amazon in the third quarter.
• Development and availability of dog treats for hospitality and travel entities by the end of the year.
• Completion of Zeranovia clinical trial and launch in the last quarter.
• Issuance of additional shares of common stock for cash and services during the next 12 months to mitigate going concern risk.
• Implementation of changes to enhance internal control over financial reporting, including appointing additional qualified personnel and adopting sufficient written policies and procedures, contingent on securing additional financing.

Key Dates

Recommendation

The company is in a precarious financial state, evidenced by a 'going concern' warning from its auditors, a substantial accumulated deficit of over $9.5 million, and a significant increase in operating losses despite a net loss improvement driven by non-operational derivative gains. Revenue has plummeted, and the company is in default on existing convertible debt. While new products are being launched, the fundamental financial health is extremely weak, and the ability to continue operations is highly dependent on securing additional, uncertain financing. Material weaknesses in internal controls further exacerbate the risk profile. These factors collectively indicate a high probability of further share price depreciation and significant risk to investors' capital.

Keywords

Nutraceuticals, Dietary Supplements, Medical Devices, Health and Wellness, SEC Filing, 10-Q, BioAdaptives, Going Concern, Preferred Stock, Convertible Notes, PawPa Regen, MyndMed, Xcellara, Zeranovia, Lung Flute